Sloning Biotechnology and Microsynth Announce Exclusive Distribution Partnership for Switzerland
News Jun 04, 2007
Microsynth will exclusively market and sell Sloning's gene synthesis service (Slonomics™) and the product family of mutant libraries (Slonomax™) in Switzerland.
“We are very pleased that Microsynth will join our global network of qualified distributors. With its strong technological expertise, market position and service philosophy Microsynth is the ideal partner for Sloning to develop the Swiss market,” stated Thomas Matthes, the company CBO.
Dr. Tobias Schmidheini, founder and CEO of Microsynth said, “Sloning´s products and services perfectly complement our portfolio. It’s a strategic development for our organization. We are looking forward to offering Sloning´s products to our customer base.”
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE